Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.

Mózner O, Bartos Z, Zámbó B, Homolya L, Hegedűs T, Sarkadi B.

Cells. 2019 Oct 8;8(10). pii: E1215. doi: 10.3390/cells8101215. Review.

2.

Discovering the chloride pathway in the CFTR channel.

Farkas B, Tordai H, Padányi R, Tordai A, Gera J, Paragi G, Hegedűs T.

Cell Mol Life Sci. 2019 Jul 20. doi: 10.1007/s00018-019-03211-4. [Epub ahead of print]

PMID:
31327045
3.

MemBlob database and server for identifying transmembrane regions using cryo-EM maps.

Farkas B, Csizmadia G, Katona E, Tusnády GE, Hegedűs T.

Bioinformatics. 2019 Jul 10. pii: btz539. doi: 10.1093/bioinformatics/btz539. [Epub ahead of print]

PMID:
31290936
4.

Chemically Modified Derivatives of the Activator Compound Cloxyquin Exert Inhibitory Effect on TRESK (K2P18.1) Background Potassium Channel.

Lengyel M, Erdélyi F, Pergel E, Bálint-Polonka Á, Dobolyi A, Bozsaki P, Dux M, Király K, Hegedűs T, Czirják G, Mátyus P, Enyedi P.

Mol Pharmacol. 2019 Jun;95(6):652-660. doi: 10.1124/mol.118.115626. Epub 2019 Apr 12.

PMID:
30979812
5.

Quantitative comparison of ABC membrane protein type I exporter structures in a standardized way.

Csizmadia G, Farkas B, Spagina Z, Tordai H, Hegedűs T.

Comput Struct Biotechnol J. 2018 Oct 18;16:396-403. doi: 10.1016/j.csbj.2018.10.008. eCollection 2018.

6.

Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.

Zámbó B, Bartos Z, Mózner O, Szabó E, Várady G, Poór G, Pálinkás M, Andrikovics H, Hegedűs T, Homolya L, Sarkadi B.

Sci Rep. 2018 May 10;8(1):7487. doi: 10.1038/s41598-018-25695-z.

7.

Transcriptome analysis of inflammation-related gene expression in endothelial cells activated by complement MASP-1.

Schwaner E, Németh Z, Jani PK, Kajdácsi E, Debreczeni ML, Doleschall Z, Dobó J, Gál P, Rigó J, András K, Hegedűs T, Cervenak L.

Sci Rep. 2017 Sep 5;7(1):10462. doi: 10.1038/s41598-017-09058-8.

8.

GLUT10-Lacking in Arterial Tortuosity Syndrome-Is Localized to the Endoplasmic Reticulum of Human Fibroblasts.

Gamberucci A, Marcolongo P, Németh CE, Zoppi N, Szarka A, Chiarelli N, Hegedűs T, Ritelli M, Carini G, Willaert A, Callewaert BL, Coucke PJ, Benedetti A, Margittai É, Fulceri R, Bánhegyi G, Colombi M.

Int J Mol Sci. 2017 Aug 22;18(8). pii: E1820. doi: 10.3390/ijms18081820.

9.

Molecular dynamics of the cryo-EM CFTR structure.

Tordai H, Leveles I, Hegedűs T.

Biochem Biophys Res Commun. 2017 Sep 30;491(4):986-993. doi: 10.1016/j.bbrc.2017.07.165. Epub 2017 Jul 31.

PMID:
28774558
10.

ABCMdb reloaded: updates on mutations in ATP binding cassette proteins.

Tordai H, Jakab K, Gyimesi G, András K, Brózik A, Sarkadi B, Hegedus T.

Database (Oxford). 2017 Jan 1;2017(1). doi: 10.1093/database/bax023.

11.

Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.

László L, Sarkadi B, Hegedűs T.

PLoS One. 2016 Oct 14;11(10):e0164426. doi: 10.1371/journal.pone.0164426. eCollection 2016.

12.

Correction: A systematic study of protein labeling by fluorogenic probes using cysteine targeting vinyl sulfone-cyclooctyne tags.

Söveges B, Imre T, Szende T, Póti ÁL, Cserép GB, Hegedűs T, Kele P, Németh K.

Org Biomol Chem. 2016 Sep 26;14(38):9158.

PMID:
27714347
13.

A systematic study of protein labeling by fluorogenic probes using cysteine targeting vinyl sulfone-cyclooctyne tags.

Söveges B, Imre T, Szende T, Póti ÁL, Cserép GB, Hegedűs T, Kele P, Németh K.

Org Biomol Chem. 2016 Jul 7;14(25):6071-8. doi: 10.1039/c6ob00810k. Epub 2016 May 31. Erratum in: Org Biomol Chem. 2016 Sep 26;14(38):9158.

PMID:
27244693
14.

Adjustment errors of sunstones in the first step of sky-polarimetric Viking navigation: studies with dichroic cordierite/ tourmaline and birefringent calcite crystals.

Száz D, Farkas A, Blahó M, Barta A, Egri Á, Kretzer B, Hegedüs T, Jäger Z, Horváth G.

R Soc Open Sci. 2016 Jan 20;3(1):150406. doi: 10.1098/rsos.150406. eCollection 2016 Jan.

15.

Access Path to the Ligand Binding Pocket May Play a Role in Xenobiotics Selection by AhR.

Szöllősi D, Erdei Á, Gyimesi G, Magyar C, Hegedűs T.

PLoS One. 2016 Jan 4;11(1):e0146066. doi: 10.1371/journal.pone.0146066. eCollection 2016.

16.

The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Macalou S, Robey RW, Jabor Gozzi G, Shukla S, Grosjean I, Hegedus T, Ambudkar SV, Bates SE, Di Pietro A.

Cell Mol Life Sci. 2016 May;73(9):1927-37. doi: 10.1007/s00018-015-2118-5. Epub 2015 Dec 26.

PMID:
26708291
17.

Inconsistencies in the red blood cell membrane proteome analysis: generation of a database for research and diagnostic applications.

Hegedűs T, Chaubey PM, Várady G, Szabó E, Sarankó H, Hofstetter L, Roschitzki B, Stieger B, Sarkadi B.

Database (Oxford). 2015 Jun 14;2015:bav056. doi: 10.1093/database/bav056. Print 2015.

18.

A novel mathematical model describing adaptive cellular drug metabolism and toxicity in the chemoimmune system.

Tóth A, Brózik A, Szakács G, Sarkadi B, Hegedüs T.

PLoS One. 2015 Feb 20;10(2):e0115533. doi: 10.1371/journal.pone.0115533. eCollection 2015.

19.

Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.

Hegedüs C, Telbisz Á, Hegedűs T, Sarkadi B, Özvegy-Laczka C.

Adv Cancer Res. 2015;125:97-137. doi: 10.1016/bs.acr.2014.10.004. Epub 2015 Jan 8. Review.

PMID:
25640268
20.

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, Finkbeiner WE, Hegedus T, Verkman AS, Lukacs GL.

Sci Transl Med. 2014 Jul 23;6(246):246ra97. doi: 10.1126/scitranslmed.3008889.

21.

Discrete molecular dynamics can predict helical prestructured motifs in disordered proteins.

Szöllősi D, Horváth T, Han KH, Dokholyan NV, Tompa P, Kalmár L, Hegedűs T.

PLoS One. 2014 Apr 24;9(4):e95795. doi: 10.1371/journal.pone.0095795. eCollection 2014.

22.

Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.

Sarankó H, Tordai H, Telbisz Á, Özvegy-Laczka C, Erdős G, Sarkadi B, Hegedűs T.

Biochem Biophys Res Commun. 2013 Jul 19;437(1):140-5. doi: 10.1016/j.bbrc.2013.06.054. Epub 2013 Jun 22.

PMID:
23800412
23.

Mechanism-based corrector combination restores ΔF508-CFTR folding and function.

Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, Hegedus T, Beekman JM, Lukacs GL.

Nat Chem Biol. 2013 Jul;9(7):444-54. doi: 10.1038/nchembio.1253. Epub 2013 May 12.

24.

Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.

Telbisz Á, Özvegy-Laczka C, Hegedűs T, Váradi A, Sarkadi B.

Biochem J. 2013 Mar 1;450(2):387-95. doi: 10.1042/BJ20121485.

PMID:
23205634
25.

Potential application of network descriptions for understanding conformational changes and protonation states of ABC transporters.

Hegedűs T, Gyimesi G, Gáspár ME, Szalay KZ, Gangal R, Csermely P.

Curr Pharm Des. 2013;19(23):4155-72. Review.

PMID:
23170883
26.

ABCMdb: a database for the comparative analysis of protein mutations in ABC transporters, and a potential framework for a general application.

Gyimesi G, Borsodi D, Sarankó H, Tordai H, Sarkadi B, Hegedűs T.

Hum Mutat. 2012 Nov;33(11):1547-56. doi: 10.1002/humu.22138. Epub 2012 Jul 11.

PMID:
22693078
27.

ATP hydrolysis at one of the two sites in ABC transporters initiates transport related conformational transitions.

Gyimesi G, Ramachandran S, Kota P, Dokholyan NV, Sarkadi B, Hegedus T.

Biochim Biophys Acta. 2011 Dec;1808(12):2954-64. doi: 10.1016/j.bbamem.2011.07.038. Epub 2011 Aug 3. Erratum in: Biochim Biophys Acta. 2012 May;1818(5):1435.

28.

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G, Sarkadi B.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):623-42. doi: 10.1517/17425255.2011.562892. Epub 2011 Mar 17. Review.

PMID:
21410427
29.

Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A.

Hegedus T, Aleksandrov A, Mengos A, Cui L, Jensen TJ, Riordan JR.

Biochim Biophys Acta. 2009 Jun;1788(6):1341-9. doi: 10.1016/j.bbamem.2009.03.015. Epub 2009 Mar 26.

30.

Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating.

He L, Aleksandrov AA, Serohijos AW, Hegedus T, Aleksandrov LA, Cui L, Dokholyan NV, Riordan JR.

J Biol Chem. 2008 Sep 26;283(39):26383-90. doi: 10.1074/jbc.M803894200. Epub 2008 Jul 25.

31.

Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.

Ozvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Váradi A, Sarkadi B.

J Biol Chem. 2008 Sep 19;283(38):26059-70. doi: 10.1074/jbc.M803230200. Epub 2008 Jul 21.

32.

Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding.

Serohijos AW, Hegedus T, Riordan JR, Dokholyan NV.

PLoS Comput Biol. 2008 Feb 29;4(2):e1000008. doi: 10.1371/journal.pcbi.1000008.

33.

Computational studies reveal phosphorylation-dependent changes in the unstructured R domain of CFTR.

Hegedus T, Serohijos AW, Dokholyan NV, He L, Riordan JR.

J Mol Biol. 2008 May 16;378(5):1052-63. doi: 10.1016/j.jmb.2008.03.033. Epub 2008 Mar 26.

34.

Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, Riordan JR.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3256-61. doi: 10.1073/pnas.0800254105. Epub 2008 Feb 27.

35.

Domain interdependence in the biosynthetic assembly of CFTR.

Cui L, Aleksandrov L, Chang XB, Hou YX, He L, Hegedus T, Gentzsch M, Aleksandrov A, Balch WE, Riordan JR.

J Mol Biol. 2007 Jan 26;365(4):981-94. Epub 2006 Nov 10.

PMID:
17113596
36.

F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive.

Hegedus T, Aleksandrov A, Cui L, Gentzsch M, Chang XB, Riordan JR.

Biochim Biophys Acta. 2006 May;1758(5):565-72. Epub 2006 Mar 31.

37.

HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene.

Kalmár L, Hegedüs T, Farkas H, Nagy M, Tordai A.

Hum Mutat. 2005 Jan;25(1):1-5.

PMID:
15580551
38.

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K, Sarkadi B.

Mol Pharmacol. 2004 Jun;65(6):1485-95.

PMID:
15155841
39.

C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins.

Hegedüs T, Sessler T, Scott R, Thelin W, Bakos E, Váradi A, Szabó K, Homolya L, Milgram SL, Sarkadi B.

Biochem Biophys Res Commun. 2003 Mar 14;302(3):454-61.

PMID:
12615054
40.

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):318-25. Review.

41.

Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1.

Holló Z, Homolya L, Hegedûs T, Müller M, Szakács G, Jakab K, Antal F, Sarkadi B.

Anticancer Res. 1998 Jul-Aug;18(4C):2981-7.

PMID:
9713496
42.

Membrane topology and glycosylation of the human multidrug resistance-associated protein.

Bakos E, Hegedüs T, Holló Z, Welker E, Tusnády GE, Zaman GJ, Flens MJ, Váradi A, Sarkadi B.

J Biol Chem. 1996 May 24;271(21):12322-6.

43.

Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.

Holló Z, Homolya L, Hegedüs T, Sarkadi B.

FEBS Lett. 1996 Mar 25;383(1-2):99-104.

44.

[The question of managing the placental stage of delivery].

Forgách J, Hajnóczky K, Hegedüs T, Krasznai P.

Orv Hetil. 1992 Oct 25;133(43):2793-4. Hungarian. No abstract available.

PMID:
1408106
45.

[Relationship between the management of the placental phase and the frequency of indication for uterine intervention in the puerperium].

Forgách J, Hajnáczky K, Hegedüs T, Krasznai P.

Orv Hetil. 1992 Feb 25;133(8):467-70. Review. Hungarian.

PMID:
1542510
46.

[Cytological analysis of peritoneal lavage fluid in patients during operation for cancer of the myometrium].

Forgách J, Hegedüs T, Krasznai P, Nádor K, Zacher P.

Orv Hetil. 1991 Jun 9;132(23):1253-6. Review. Hungarian.

PMID:
1852437
47.

[Current problems and complications of extensive uterine and pelvic lymph node excision for cancer of the uterus based on a 25-year case load].

Forgách J, Hegedüs T, Krasznai P, Zacher P.

Orv Hetil. 1990 Sep 23;131(38):2079-84. Review. Hungarian.

PMID:
2216435
49.

Inhibition of N-diethylnitrosamine metabolism by human lung cancer cell lines with features of well differentiated pulmonary endocrine cells.

Hegedus TJ, Falzon M, Margaretten N, Gazdar AF, Schuller HM.

Biochem Pharmacol. 1987 Oct 15;36(20):3339-43.

PMID:
2823818
50.

Cell type-specific differences in metabolic activation of N-nitrosodiethylamine by human lung cancer cell lines.

Schuller HM, Falzon M, Gazdar AF, Hegedus T.

IARC Sci Publ. 1987;(84):138-40.

PMID:
2824357

Supplemental Content

Loading ...
Support Center